Free tool
FAERS Monitor: Zirgan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022211 or its brand name (Zirgan, Ganciclovir). Reports on generic versions are filed under their own applications.
Reports
10,361
Serious
9,837
95% of reports
Hospitalization
4,195
Death reported
3,155
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,720
- drug ineffective1,484
- cytomegalovirus infection1,208
- drug resistance678
- pyrexia607
- product use in unapproved indication552
- neutropenia548
- pancytopenia525
- diarrhoea450
- cytomegalovirus viraemia434
- pneumonia429
- sepsis420
- multiple organ dysfunction syndrome416
- respiratory failure399
- cytomegalovirus infection reactivation397
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 73 |
| 2005 | 76 |
| 2006 | 109 |
| 2007 | 124 |
| 2008 | 182 |
| 2009 | 226 |
| 2010 | 158 |
| 2011 | 260 |
| 2012 | 303 |
| 2013 | 214 |
| 2014 | 234 |
| 2015 | 237 |
| 2016 | 338 |
| 2017 | 501 |
| 2018 | 607 |
| 2019 | 935 |
| 2020 | 1,023 |
| 2021 | 938 |
| 2022 | 858 |
| 2023 | 850 |
| 2024 | 848 |
| 2025 | 799 |
| 2026 | 466 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,798 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus viraemiaSignal | 434 | 219.3 | 199.0 | 84,950 |
| cytomegalovirus infection reactivationSignal | 397 | 200.3 | 181.0 | 71,504 |
| cytomegalovirus infectionSignal | 1,208 | 159.0 | 150.5 | 175,907 |
| drug resistanceSignal | 678 | 55.0 | 51.1 | 34,992 |
| multiple organ dysfunction syndromeSignal | 416 | 30.2 | 27.5 | 11,576 |
| pancytopeniaSignal | 525 | 19.2 | 17.7 | 9,000 |
| respiratory failureSignal | 399 | 11.2 | 10.1 | 3,674 |
| neutropeniaSignal | 548 | 8.2 | 7.6 | 3,472 |
| sepsisSignal | 420 | 7.7 | 7.0 | 2,433 |
| product use in unapproved indicationSignal | 552 | 4.5 | 4.2 | 1,529 |
| off label useSignal | 1,720 | 4.0 | 3.8 | 4,016 |
| pyrexiaSignal | 607 | 3.6 | 3.3 | 1,135 |
| pneumoniaSignal | 429 | 2.7 | 2.5 | 461 |
| drug ineffectiveSignal | 1,484 | 2.3 | 2.2 | 1,144 |
| diarrhoea | 450 | 1.4 | 1.3 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.